August 26, 2025 – For the first time in Israel, Rambam Health Care Campus (Rambam) is testing a revolutionary gene-editing treatment that could halt a deadly form of heart failure. The same technology may soon target The post First in Israel: Gene-Editing Therapy for Heart Failure appeared first on American Friends of Rambam Medical Center.| American Friends of Rambam Medical Center
Corvista Health’s point-of-care device, used to predict pulmonary hypertension (PH), also appears to work well at identifying heart failure.| Pulmonary Hypertension News
Kaiser Permanente study finds medication is still necessary for patients with a reduced ejection fraction that improves over time.| Kaiser Permanente Division of Research
The Aeson Total Artificial Heart helped three people with heart failure and pulmonary hypertension become eligible for a heart transplant.| Pulmonary Hypertension News
Sensydia has completed a development study of its Cardiac Performance System device to detect pulmonary hypertension and heart failure.| Pulmonary Hypertension News
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing critical needs in cardiovascular health.| News-Medical
Heart failure related to PAH is becoming more common, with patients living fewer years in full health, a trend that’s predicted to continue.| Pulmonary Hypertension News
A major new study has finally confirmed the cause of soaring heart failure cases among children that are being reported all around the world.| Slay News